TD Asset Management Inc. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.6% during the second quarter, Holdings Channel reports. The fund owned 2,200,584 shares of the company’s stock after buying an additional 96,857 shares during the period. TD Asset Management Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $73,104,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Sii Investments Inc. WI raised its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after buying an additional 25 shares during the last quarter. Salem Investment Counselors Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after buying an additional 32 shares during the last quarter. Cribstone Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. Financial Architects Inc raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. Institutional investors own 56.27% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 18.59 on Tuesday. The company has a market capitalization of $18.89 billion, a P/E ratio of 238.33 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 12-month low of $18.50 and a 12-month high of $55.45. The stock’s 50 day moving average is $32.05 and its 200-day moving average is $32.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.25 earnings per share. Analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.83%. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/08/teva-pharmaceutical-industries-limited-teva-shares-bought-by-td-asset-management-inc.html.

Several equities research analysts have recently issued reports on the stock. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target for the company. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. Barclays PLC reduced their price objective on shares of Teva Pharmaceutical Industries Limited from $38.00 to $23.00 and set an “equal weight” rating for the company in a research note on Monday. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Finally, Maxim Group reiterated a “hold” rating and issued a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $39.19.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.